AACR Special Conference in Cancer Research: Liquid Biopsy
The study demonstrated a CRISPR/Cas12a technology that selectively removes unmethylated “non-cancer” DNA while preserving methylated “cancer” signals, enhancing detection accuracy. This multiplexable method improves the sensitivity of rare methylation event detection in both qPCR and sequencing assays.
